Halloran Speaker Series: Roadmap for Success - Streamline and Expedite your Development Program
Join us on December 4th for the next edition of our Halloran Speaker Series, which will kick off a 4-part series titled Roadmap for Success: Streamline and Expedite your Development Program.
Faster, cheaper, better: How China and AI are helping pharmaceutical development
Traditionally the West has excelled in pharmaceuticals development. As AI and other technologies become mainstream in the field, however, the balance is shifting. There will be opportunities for cooperation, but competition will be strong, Mark Vermette told TechNode.
FDA Fast Track designations reach 20th year
Twenty years after its inception, the FDA’s Fast Track designation program is going strong, with many signs that it has achieved its goal of bringing novel drugs to the market faster. Now, even with a new FDA Commissioner at the helm, the Fast Track program is unlikely to change substantially...
Three questions on indication assessment
Indication assessment ensures a clear understanding of unmet medical needs, patient segmentation, and what the therapeutic profile—efficacy, safety, dosing, etc.—needs to look like to meet those needs.
Drug Development and Transactional Deal Landscape for Neurodegenerative Disorders
NDDs impact a significant number of the global population and are the leading cause of disability and morbidity in the US. There is a long history of failed attempts to develop effective therapies, and currently, there are no treatments that can prevent, slow down or cure NDDs.